EUROAPI and StrainChem enter into collaboration for liquid phase peptides

January 30, 2025

EUROAPI has signed a key collaboration with StrainChem, a French Contract Research Organization (CRO) in organic green chemistry founded in 2017. Through this agreement, EUROAPI gains access to StrainChem cutting-edge Sustainable Liquid Phase Peptide Synthesis (SLiPPS) proprietary technology. Peptides are large molecules with complex structures and various therapeutic applications including oncology, genetic disorders, metabolic and infectious diseases.

The SLiPPS approach ensures both a significant reduction of organic solvents consumption vs Solid Phase Peptide Synthesis (SPPS), and a more efficient peptide manufacturing process thanks to better synthesis control, faster reaction kinetics resulting in lower raw material consumption, energy and time savings. Under the partnership EUROAPI and StrainChem are joining forces to offer their customers a peptide one-stop-shop solution, from proof of concept to industrial scale, covering both pharmaceutical and cosmetic fields.

“This is a win-win collaboration as EUROAPI will support the promotion of early-stage services of StrainChem and StrainChem will support the promotion of industrial scale services of EUROAPI. Ultimately, our partnership will be beneficial for both companies as each party could bring projects to the other party,” explains Simon Dossin, Strategy Platform Leader for the Tides platform with EUROAPI.

In addition to introducing sustainable innovation to EUROAPI’s technology portfolio, this collaboration will reinforce EUROAPI’s tide platform, a priority segment for its Contract Development and Manufacturing Organization (CDMO) business. Drawing on 45 years of experience in the field of peptides, EUROAPI provides a unique state-of-the-art platform for their development and scale-up at Hoechst Industrial Park in Frankfurt (Germany). This site is a pioneer in solid-phase synthesis and is regularly inspected by the FDA as well as by other international and European agencies.

Find out more in the Research article: Advancing Sustainability in Peptide Synthesis

About EUROAPI

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.